These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24850086)

  • 1. Response to letter by Wang et al.: Comparing cardioprotection by remote ischaemic preconditioning in patients with and without diabetics.
    Kottenberg E; Peters J
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):769. PubMed ID: 24850086
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing cardioprotection by remote ischaemic pre-conditioning in patients with and without diabetes.
    Wang SY; Xue FS; Cui XL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):768. PubMed ID: 24773561
    [No Abstract]   [Full Text] [Related]  

  • 3. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation.
    Kottenberg E; Thielmann M; Kleinbongard P; Frey UH; Heine T; Jakob H; Heusch G; Peters J
    Acta Anaesthesiol Scand; 2014 Apr; 58(4):453-62. PubMed ID: 24548338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
    Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA
    Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and coronary artery disease: time to stop taking the tablets.
    Edwards RJ; Rakhit RD; Marber MS
    Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
    [No Abstract]   [Full Text] [Related]  

  • 6. Exogenous calcium preconditions myocardium from patients taking oral sulfonylurea agents.
    Cain BS; Meldrum DR; Meng X; Pulido EJ; Shames BD; Selzman CH; Banerjee A; Harken AH
    J Surg Res; 1999 Oct; 86(2):171-6. PubMed ID: 10534420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter to the Editor: Comments on "Sulfonylurea Treatment Before Genetic Testing in Neonatal Diabetes: Pros and Cons" by Carmody D, et al.
    Deeb A
    J Clin Endocrinol Metab; 2016 Mar; 101(3):L36. PubMed ID: 26938375
    [No Abstract]   [Full Text] [Related]  

  • 8. Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.
    Leonard CE; Hennessy S; Han X; Siscovick DS; Flory JH; Deo R
    Trends Endocrinol Metab; 2017 Aug; 28(8):561-586. PubMed ID: 28545784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?
    Riddle MC
    J Clin Endocrinol Metab; 2003 Feb; 88(2):528-30. PubMed ID: 12574174
    [No Abstract]   [Full Text] [Related]  

  • 10. Coronary revascularization without cardiopulmonary bypass: use of ischemic preconditioning and adenosine.
    Latham P; Joshi GP
    Anesthesiology; 1998 Mar; 88(3):828-30. PubMed ID: 9523830
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of hypoglycemic sulphonylureas in arrhythmias contributing to the mortality in acute myocardial ischemia.
    Koltai MZ; Aranyi Z; Ballagi-Podány G; Pogátsa G
    Acta Physiol Hung; 1990; 75 Suppl():175-6. PubMed ID: 2371854
    [No Abstract]   [Full Text] [Related]  

  • 12. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of myocardial protection in type 2 diabetic patients.
    Lee TM; Chou TF
    J Clin Endocrinol Metab; 2003 Feb; 88(2):531-7. PubMed ID: 12574175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Porphyria cutanea tarda and blood-sugar-suppressing derivatives of sulfonylurea].
    Malina L; Bartos V
    Hautarzt; 1975 Oct; 26(10):535-6. PubMed ID: 1201944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response letter to the editor.
    Greeley SA
    J Clin Endocrinol Metab; 2015 Jan; 100(1):L14. PubMed ID: 25559539
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to the Letter to the Editor by Deeb A.
    J Clin Endocrinol Metab; 2016 Mar; 101(3):L37. PubMed ID: 26938376
    [No Abstract]   [Full Text] [Related]  

  • 17. Can we do more for the STEMI patient than restore coronary blood flow?
    Erlinge D
    Cardiology; 2010; 116(2):101-2. PubMed ID: 20588017
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral antidiabetic drugs: preoperative stop or continue?
    Poortmans G
    Acta Anaesthesiol Belg; 2001; 52(4):403-7. PubMed ID: 11799573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter to the editor: recent advances in genetic testing and treatment of neonatal diabetes mellitus.
    Aydın BK; Darendeliler F
    J Clin Endocrinol Metab; 2015 Jan; 100(1):L13. PubMed ID: 25559538
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin as ischaemic preconditioning-mimetic.
    Zuurbier CJ
    Acta Physiol (Oxf); 2009 Feb; 195(2):203. PubMed ID: 19132958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.